ARTLClinical Trials•businesswire•
Arialys Therapeutics Publishes Preclinical Data in Nature Communications Supporting ART5803 as a First-in-Class Precision Therapeutic for Anti-NMDA Receptor Autoimmune Neuropsychiatric Disease
Sentiment:Positive (80)
Summary
LA JOLLA, Calif.--(BUSINESS WIRE)-- #ANRE--Arialys' Nature Communications Paper Supports ART5803 as a First-in-Class Precision Therapeutic for Anti-NMDAR Autoimmune Neuropsychiatric Disease
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 17, 2025 by businesswire